AU2013351062A1 - Tumor specific T-cell receptors - Google Patents
Tumor specific T-cell receptors Download PDFInfo
- Publication number
- AU2013351062A1 AU2013351062A1 AU2013351062A AU2013351062A AU2013351062A1 AU 2013351062 A1 AU2013351062 A1 AU 2013351062A1 AU 2013351062 A AU2013351062 A AU 2013351062A AU 2013351062 A AU2013351062 A AU 2013351062A AU 2013351062 A1 AU2013351062 A1 AU 2013351062A1
- Authority
- AU
- Australia
- Prior art keywords
- tcr
- cell
- human
- mutated
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 182
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 161
- 206010028980 Neoplasm Diseases 0.000 title claims description 46
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 59
- 210000004027 cell Anatomy 0.000 claims abstract description 41
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 22
- 230000009258 tissue cross reactivity Effects 0.000 claims abstract description 22
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 20
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 20
- 239000013598 vector Substances 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 230000002411 adverse Effects 0.000 claims abstract description 10
- 230000002829 reductive effect Effects 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 239000000427 antigen Substances 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 18
- 230000003053 immunization Effects 0.000 claims description 17
- 238000002649 immunization Methods 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000002659 cell therapy Methods 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 230000026683 transduction Effects 0.000 claims description 6
- 238000010361 transduction Methods 0.000 claims description 6
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims description 5
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims description 5
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 claims description 5
- 102100039236 Histone H3.3 Human genes 0.000 claims description 5
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- -1 RHOTI Proteins 0.000 claims description 5
- 102100036422 Speckle-type POZ protein Human genes 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 claims description 4
- 102100038214 Chromodomain-helicase-DNA-binding protein 4 Human genes 0.000 claims description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 4
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims description 4
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims description 4
- 101000883749 Homo sapiens Chromodomain-helicase-DNA-binding protein 4 Proteins 0.000 claims description 4
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 claims description 4
- 101001008854 Homo sapiens Kelch-like protein 6 Proteins 0.000 claims description 4
- 101000642268 Homo sapiens Speckle-type POZ protein Proteins 0.000 claims description 4
- 101000808799 Homo sapiens Splicing factor U2AF 35 kDa subunit Proteins 0.000 claims description 4
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims description 4
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 claims description 4
- 102100021070 Mediator of RNA polymerase II transcription subunit 12 Human genes 0.000 claims description 4
- 101150043994 NOS1 gene Proteins 0.000 claims description 4
- 102100022129 Ras-related C3 botulinum toxin substrate 2 Human genes 0.000 claims description 4
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 claims description 4
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000037841 lung tumor Diseases 0.000 claims description 4
- 230000000392 somatic effect Effects 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 108091059596 H3F3A Proteins 0.000 claims description 3
- 101001008857 Homo sapiens Kelch-like protein 7 Proteins 0.000 claims description 3
- 101000614988 Homo sapiens Mediator of RNA polymerase II transcription subunit 12 Proteins 0.000 claims description 3
- 101001110313 Homo sapiens Ras-related C3 botulinum toxin substrate 2 Proteins 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 208000023958 prostate neoplasm Diseases 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 208000034951 Genetic Translocation Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 210000005006 adaptive immune system Anatomy 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 208000023965 endometrium neoplasm Diseases 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 claims description 2
- 230000004481 post-translational protein modification Effects 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 210000004989 spleen cell Anatomy 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 102100027789 Kelch-like protein 7 Human genes 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 13
- 238000012546 transfer Methods 0.000 abstract description 5
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 28
- 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 20
- 101001110286 Homo sapiens Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 description 9
- 102100032762 Transformation/transcription domain-associated protein Human genes 0.000 description 9
- 101710164309 56 kDa type-specific antigen Proteins 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 5
- 238000001709 templated self-assembly Methods 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 101000658380 Homo sapiens T cell receptor alpha variable 13-1 Proteins 0.000 description 4
- 101000658429 Homo sapiens T cell receptor beta variable 3-1 Proteins 0.000 description 4
- 102100027791 Kelch-like protein 6 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 102100034849 T cell receptor alpha variable 13-1 Human genes 0.000 description 4
- 102100034887 T cell receptor beta variable 3-1 Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000009977 dual effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 101000794371 Homo sapiens T cell receptor alpha variable 5 Proteins 0.000 description 3
- 101000666668 Homo sapiens T cell receptor beta diversity 1 Proteins 0.000 description 3
- 101000645352 Homo sapiens T cell receptor beta joining 2-3 Proteins 0.000 description 3
- 101000939742 Homo sapiens T cell receptor beta variable 20-1 Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000043131 MHC class II family Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 102100030331 Mitochondrial Rho GTPase 1 Human genes 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102100027514 RNA-binding protein 10 Human genes 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 102100030178 T cell receptor alpha variable 5 Human genes 0.000 description 3
- 102100038401 T cell receptor beta diversity 1 Human genes 0.000 description 3
- 102100025770 T cell receptor beta joining 2-3 Human genes 0.000 description 3
- 102100029659 T cell receptor beta variable 20-1 Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102220555871 Cell division control protein 42 homolog_G12V_mutation Human genes 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 241000975394 Evechinus chloroticus Species 0.000 description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 2
- 101000990982 Homo sapiens Mitochondrial Rho GTPase 1 Proteins 0.000 description 2
- 101000580092 Homo sapiens RNA-binding protein 10 Proteins 0.000 description 2
- 101000658376 Homo sapiens T cell receptor alpha variable 12-2 Proteins 0.000 description 2
- 101000658378 Homo sapiens T cell receptor alpha variable 13-2 Proteins 0.000 description 2
- 101000772143 Homo sapiens T cell receptor alpha variable 17 Proteins 0.000 description 2
- 101000772109 Homo sapiens T cell receptor alpha variable 20 Proteins 0.000 description 2
- 101000645339 Homo sapiens T cell receptor beta joining 1-2 Proteins 0.000 description 2
- 101000939859 Homo sapiens T cell receptor beta variable 12-3 Proteins 0.000 description 2
- 101000658406 Homo sapiens T cell receptor beta variable 28 Proteins 0.000 description 2
- 101000606201 Homo sapiens T cell receptor beta variable 4-1 Proteins 0.000 description 2
- 101000606217 Homo sapiens T cell receptor beta variable 6-2 Proteins 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 101710166115 Mitogen-activated protein kinase 2 Proteins 0.000 description 2
- 101000753280 Mus musculus Angiopoietin-1 receptor Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102100035034 Splicing factor U2AF 26 kDa subunit Human genes 0.000 description 2
- 101710181531 Splicing factor U2AF 26 kDa subunit Proteins 0.000 description 2
- 102100034847 T cell receptor alpha variable 12-2 Human genes 0.000 description 2
- 102100034848 T cell receptor alpha variable 13-2 Human genes 0.000 description 2
- 102100029306 T cell receptor alpha variable 17 Human genes 0.000 description 2
- 102100029488 T cell receptor alpha variable 20 Human genes 0.000 description 2
- 102100026266 T cell receptor beta joining 1-2 Human genes 0.000 description 2
- 102100029696 T cell receptor beta variable 12-3 Human genes 0.000 description 2
- 102100034880 T cell receptor beta variable 28 Human genes 0.000 description 2
- 102100039738 T cell receptor beta variable 4-1 Human genes 0.000 description 2
- 102100039748 T cell receptor beta variable 6-2 Human genes 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102220004886 rs587776806 Human genes 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 101710081913 AT-rich interactive domain-containing protein 1A Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102100028712 Cytosolic purine 5'-nucleotidase Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100039436 DNA-binding protein inhibitor ID-3 Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 101100456569 Drosophila melanogaster kto gene Proteins 0.000 description 1
- 102100024816 E3 ubiquitin-protein ligase TRAF7 Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100032611 Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Human genes 0.000 description 1
- 102100034535 Histone H3.1 Human genes 0.000 description 1
- 101710155878 Histone acetyltransferase p300 Proteins 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 1
- 101000915162 Homo sapiens Cytosolic purine 5'-nucleotidase Proteins 0.000 description 1
- 101000830899 Homo sapiens E3 ubiquitin-protein ligase TRAF7 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 description 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 description 1
- 101001062353 Homo sapiens Hepatocyte nuclear factor 3-alpha Proteins 0.000 description 1
- 101001067844 Homo sapiens Histone H3.1 Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 description 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 description 1
- 101100247238 Homo sapiens RAD17 gene Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000620662 Homo sapiens Serine/threonine-protein phosphatase 6 catalytic subunit Proteins 0.000 description 1
- 101000651890 Homo sapiens Slit homolog 2 protein Proteins 0.000 description 1
- 101000651893 Homo sapiens Slit homolog 3 protein Proteins 0.000 description 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 description 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 description 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
- 101000836154 Homo sapiens Transforming acidic coiled-coil-containing protein 1 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108050003876 Kelch-like protein 6 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179284 Mediator of RNA polymerase II transcription subunit 12 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108700037275 Mitochondrial Rho GTPase 1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 101100165729 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) stk-1 gene Proteins 0.000 description 1
- 102100022678 Nucleophosmin Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000486442 Parastichtis suspecta Species 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 208000029464 Pulmonary infiltrates Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 101710203305 RNA-binding protein 10 Proteins 0.000 description 1
- 102220577400 RNA-binding protein 10_P30L_mutation Human genes 0.000 description 1
- 101710091141 Ras-related C3 botulinum toxin substrate 2 Proteins 0.000 description 1
- 102220510427 Ras-related C3 botulinum toxin substrate 2_P29L_mutation Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 102100022345 Serine/threonine-protein phosphatase 6 catalytic subunit Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108700011893 Slit homolog 2 Proteins 0.000 description 1
- 102100027340 Slit homolog 2 protein Human genes 0.000 description 1
- 102100032799 Smoothened homolog Human genes 0.000 description 1
- 101710181896 Speckle-type POZ protein Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100029337 Thyrotropin receptor Human genes 0.000 description 1
- 101710122029 Transcription activator BRG1 Proteins 0.000 description 1
- 102100027049 Transforming acidic coiled-coil-containing protein 1 Human genes 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220354690 c.160C>G Human genes 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000000329 lymphopenic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102220198130 rs104894340 Human genes 0.000 description 1
- 102220198117 rs1057519874 Human genes 0.000 description 1
- 102220198312 rs1057519971 Human genes 0.000 description 1
- 102220198311 rs1057519972 Human genes 0.000 description 1
- 102200127349 rs11547328 Human genes 0.000 description 1
- 102200044935 rs121913400 Human genes 0.000 description 1
- 102200044943 rs121913400 Human genes 0.000 description 1
- 102220198036 rs121913400 Human genes 0.000 description 1
- 102200026940 rs148685531 Human genes 0.000 description 1
- 102200044877 rs28931589 Human genes 0.000 description 1
- 102200092683 rs371769427 Human genes 0.000 description 1
- 102220066023 rs76776637 Human genes 0.000 description 1
- 102220074603 rs778256566 Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The present invention relates to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids encoding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as their use is the treatment of tumorous diseases.
Description
WO 2014/083173 PCT/EP2013/075141 TUMOR SPECIFIC T-CELL RECEPTORS FIELD OF THE INVENTION The present invention pertains to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids en coding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as the use of these compounds in the treatment of tumorous diseases. DESCRIPTION Despite remarkable technological advancements in the diagnosis and treatment options avail able to patients diagnosed with cancer, the prognosis still often remains poor and many pa tients cannot be cured. Immunotherapy holds the promise of offering a potent, yet targeted, treatment to patients diagnosed with various tumors, with the potential to eradicate the malig nant tumor cells without damaging normal tissues. In theory the T cells of the immune system are capable of recognizing protein patterns specific for tumor cells and to mediate their de struction through a variety of effector mechanisms. Adoptive T-cell therapy is an attempt to harness and amplify the tumor-eradicating capacity of a patient's own T cells and then return these effectors to the patient in such a state that they effectively eliminate residual tumor, however without damaging healthy tissue. Although this approach is not new to the field of tumor immunology, still many drawbacks in the clinical use of adoptive T cell therapy impair the full use of this approach in cancer treatments. A TCR is a heterodimeric cell surface protein of the immunoglobulin super-family which is associated with invariant proteins of the CD3 complex involved in mediating signal transduc tion. TCRs exist in ap and y6 forms, which are structurally similar but have quite distinct ana tomical locations and probably functions. The extracellular portion of native heterodimeric ajTCR consists of two polypeptides, each of which has a membrane-proximal constant do main, and a membrane-distal variable domain. Each of the constant and variable domains in cludes an intra-chain disulfide bond. The variable domains contain the highly polymorphic WO 2014/083173 - 2 - PCT/EP2013/075141 loops analogous to the complementarity determining regions (CDRs) of antibodies. The use of TCR gene therapy overcomes a number of current hurdles. It allows equipping patients' own T cells with desired specificities and generation of sufficient numbers of T cells in a short period of time, avoiding their exhaustion. The TCR will be transduced into central memory T cells or T cells with stem cell characteristics, which may ensure better persistence and function upon transfer. TCR-engineered T cells will be infused into cancer patients ren dered lymphopenic by chemotherapy or irradiation, allowing efficient engraftment but inhibit ing immune suppression. Transgenic mice expressing human MHC molecules and a diverse human TCR repertoire serve as a tool to rapidly analyze whether peptide antigens are immu nogenic, i.e. are they efficiently processed and presented by MHC molecules, do they effi ciently induce T cell responses following immunization (Li et al. 2010 Nat Med). Using the human TCR transgenic mouse, any human peptide sequence not encoded by the mouse genome is suitable for immunization and will yield TCRs with optimal affinity. Opti mal affinity means that the T cells are restricted to human self-MHC molecules and recognize the peptide antigen as foreign, e.g. represent the non-tolerant repertoire. By using pep tide/MHC multimers, specific T cells of the transgenic mice can be sorted, human TCRs iso lated, e.g. by single cell PCR, the TCRs optimized for efficient expression while avoiding mispairing with endogenous TCR and used for transduction of patients' T cells with viral vec tors (Uckert et al. 2008 Cancer Immunol Immunother; Kammertoens T et al. 2009 Eur J Im munol). The key problem of ATT is to target the right antigen to prevent tumor recurrence and toxic side effects. This sounds simple given the large number of putative tumor antigens. However, most are tumor-associated (self) antigens (TAAs). TAAs are also expressed by normal cells. Expression by rare but vital cells has usually not been analyzed. Moreover, TAA expression may be heterogeneous within the tumor/metastases of a given individual. Thus, targeting TAAs bears the risk of ineffective long-term responses and destruction of normal tissues. Clinical trials with TCR (or chimeric antibody receptor; CAR)-engineered T cells, e.g. di rected against Melan-A/MART-1, gp 100, HER-2 and carcinoembryonic antigen, support this assumption.
WO 2014/083173 - - PCT/EP2013/075141 Morgan RA and colleagues present a case report on a patient with ERBB2 overexpressing cancer that was treated by infusing T cells transduced with a chimeric antigen receptor recog nizing ERBB2 into the patient. After 15 minutes of the infusion the patient experienced res piratory distress and dramatic pulmonary infiltrate. The patient died after 5 days. This dra matic outcome underlines the problem of toxic adverse effects in the context of adoptive T cell therapy. Another approach makes use of the immunization of mice, the subsequent isolation of the T cells and T cell receptors from these cells, in order to transduce autologous peripheral lym phocytes of a tumor patient. The transduced lymphocytes were expanded and then re-infused. Although tumor regression was observed, the patients still showed the destruction of normal cells (Johnson LA et al. 2009 Blood). Parkhurst and colleagues (2010 Mol Ther) genetically engineered autologous T lymphocytes of patients suffering from metastatic colorectal cancer refractory to standard treatments. The T lymphocytes were altered to express a murine T cell receptor directed at the carcinoembryonic antigen (CEA). Again the report shows regression of the tumor, however with severe transient inflammatory colitis as side effect in all patients. Thus, for many, if not most, tumor associated antigens substantial toxicity by effective adop tive T cell therapy is predictable. In view of the above described major drawbacks in the background art, it is the objective of the present invention to provide novel approaches for adoptive T-cell therapy which can over come the severe side effects observed in immune therapy when genetically engineered T cell receptors are introduced into autologous lymphocytes and re-infused into a human patient. A more specified object of the present invention is to provide novel antigen recognizing con structs which specifically target tumor cells and not healthy cells. In a first aspect of the present invention, the above objective is solved by a method for the production of a human T cell receptor (TCR) or a T-cell, which is specific for tumorous cells and has reduced adverse effects in adoptive T-cell therapy, comprising the method steps of a. Providing a host organism expressing un-rearranged human TCR loci, WO 2014/083173 PCT/EP2013/075141 b. Immunizing said host organism with a peptide comprising an epitope specific for a tumor specific antigen (TSA), c. Isolating from said host organism or cell a T cell clone having an activity against said human mutated TSA, d. Optionally, isolating from said T cell clone the TCR, wherein said TSA is selected out of the class of somatic mutated antigens. The surprising finding of the present invention is that if, by contrast to the state of the art ap proaches, mutant cancer-driving oncogenes, specifically TSAs out of the class of somatic mu tated antigens, are targeted by adoptive T cell therapy (ATT), many of the problems with TAAs as known in the state of the art are resolved. Except for antigens encoded by cancer viruses, mutated antigens are the only exclusively tumor-specific antigens. Of course, the TCRs produced in accordance with the herein described method of the inven tion do not only provide their advantageous effects in adoptive T cell therapy, but also in any other therapeutic approach wherein the specific binding of the TCR to its target is employed. The TCRs isolated in accordance with the method of the present invention are advantageous over the state of the art antigen recognizing constructs due to their reduced risk for adverse effects which are observed in adoptive T cell therapy. Adverse effects in context of adoptive T cell transfers are mainly due to autoimmune reactions or to off-target reactions. The present invention specifically intends to solve the former problem by providing T cells which are highly specific to tumor cells and do not mediate an immune reaction against a patient's healthy tissue. Adverse events following infusion of human autologous or allogeneic lym phocytes that the present invention seeks to reduce can be various. In a preferred embodiment of the present invention the TCR obtained by the present invention provide a reduced risk when used in adoptive T cell therapy for inducing healthy tissue damage, which might result in edema and necrosis. In one preferred embodiment of the present invention said host organism further comprises a transgene for the expression of a human major histocompatibility complex (MHC) class I or II allele. Preferably the MHC is a human leucocyte antigen (HLA) type which is known or sus pected to be able to present said mutated TSA. Even more preferred is that the HLA type which is expressed in said host organism is known or suspected to be able to present a peptide WO 2014/083173 PCT/EP2013/075141 derived from said mutated TSA. This peptide should comprise an amino acid sequence in cluding the mutation which is specifically present in the mutated TSA opposed to the corre sponding un-mutated (wild type) version of the same protein. HLAs corresponding to MHC class I comprise the types A, B, and C. HLA class I complexes present peptides which are processed inside the presenting cell (including alien peptides'such as viral peptides if present). In general, such HLA class I peptides are small polymers, about 9 amino acids in length. HLAs corresponding to MHC class II comprise the types DP, DM, DOA, DOB, DQ, and DR. HLA class II complexes present antigens originating from the out side of the cell. They can be of a length between 12 and 18 amino acids. The characterization of the responsible HLA alleles presenting an antigen of choice is a methodology generally known in the art. In said host organism used in accordance with the present invention - insofar it is not a hu man - the un-rearranged human TCR loci are preferably present as one or more transgenes in the genome of said host organism. Preferably these loci encode TCR a and 0 chains, and pref erably comprise a plurality, ideally all, of human TCR V, D, J, and/or C genes. For the method in accordance with the present invention it is preferably a prerequisite that said host organism has an adaptive immune system and/or is able to mount a VDJC rear rangement within said human TCR loci. Furthermore a host organism is preferred which is able to express heterologous TCRs. In certain preferred embodiments of the invention said host organism is a transgenic animal, preferably a mammal, more preferably a non-human mammal, most preferably a mouse, a rat, a donkey, a rabbit, a hare or a monkey, or any ani mal which is known in the art to be a host for the generation of T-cells. In the context of such embodiments of the invention which relate to the above method and wherein non-human host organisms are used, such a non-human host organism preferably further comprises inactivated endogenous TCR loci, preferably wherein said endogenous TCR loci encode for the TCR a and 0 chains of said non-human host organism. In one very specific embodiment of the present invention said host-organism is an "ABabDII" mouse. The term "ABabDII" mouse refers to the transgenic animal produced as described in Li et al., 2010;16:1029-34 Nature Medicine. Of course it is understood that also any other WO 2014/083173 - 6 - PCT/EP2013/075141 transgenic animal produced with the same methodology as described in Li et al. shall be en compassed as a suitable host organism for use in the herein described embodiments of the invention. An alternative embodiment relates to a method, wherein a human, for example a healthy indi vidual or a human patient suffering from a tumorous disease, is immunized with said peptide as described herein. In this embodiment T cells can be isolated subsequent to the immuniza tion process from the blood of the human subject. This embodiment has the advantage that the improved T cell receptor is expressed on human, ideally autologous, T cells which can then be used for reinfusion in adoptive T cell therapy. The peptide used for the immunization of the host organism in context of the method of the present invention comprises an amino acid sequence which is in at least one amino acid resi due mutated compared to the amino acid sequence of the corresponding wild-type cellular protein. The present invention relates to the use of tumor specific antigens, therefore proteins which were mutated in the development of tumor cells and thus in this specific mutated form exclusively are present in tumor cells. Normal, healthy, cells however might still express the original un-mutated (wild type) protein. Thus, for the herein described invention it is specifi cally preferred that the peptide used for immunization comprises in its sequence the mutation which differentiates the TSA from the original un-mutated cellular protein. Preferred peptides for use in the method of the invention comprise any of the sequences shown in SEQ ID No. 1 to 27. In preferred embodiments of the invention the peptide for immunization comprises the amino acid sequence shown in SEQ ID No. 1. Antigens which are specifically expressed in tumor cells and not in healthy tissue can be cate gorized into four types: (I) mutated antigens develop during tumor-genesis by point mutations or translocations within the tumor cells. Those antigens are strictly tumor-specific. In the con text of the invention these antigens are referred to as tumor specific antigens (TSA). (II) can cer/germline antigens are usually expressed solely within the germ cells of an adult organism and not in healthy somatic tissue. In cancer cells, however, due to the loss of epigenetic regu lation, germ-cell specific genes can be activated. (III) differentiation antigens are expressed in tumors and their healthy progenitor cells. CTL responses against such antigens often result in auto-immune reactions. (IV) overexpressed TAA show only minor expression in healthy cells WO 2014/083173 PCT/EP2013/075141 whereas in a tumor those antigens are strongly activated. For the present invention it is pre ferred that only antigens of the first type are used. For the invention TSAs formed by any kind of mutation are comprised. For merely illustrative reasons the following types of mutations are described: amino acid substitution, deletion, ad dition, insertion, or chemical or post-translational modification. Furthermore included are chromosomal translocations and exclusively in tumor cells expressed splice variants, for ex ample which occur by unspecific splicing mutations resulting in new splice sites. For the immunization process said peptide can have any length. A minimum requirement is however the presence of the epitope containing the above mentioned mutated sequence. Pre ferred peptides of the invention have a length of 100 amino acids, preferably of 50 amino ac ids, more preferably of 30 amino acids, even more preferably 8 to 16 amino acids. The exact peptide length might vary depending on whether the TSA is MHC class I or MHC class II presented. In order to enhance immunization of the host organism, it is preferred that an adjuvant is used together with the peptide. An adjuvant is for example, without being limiting thereto, CpG and/or incomplete Freunds adjuvant. After the initial immunization with the peptide, said host organisms is treated preferably at least one or two, three or four more times with said peptide and/or the adjuvant of choice. Freund's adjuvant is a solution of (mineral) oil wherein the antigen for immunization is emulsified. Incomplete Freund's adjuvant, as preferably used in this invention, does not contain any mycobacterial components. During and after the immunization process said host-organism should develop T cells ex pressing rearranged T cell receptors specific against the TSA of the invention. Such T-cell clones are then in a preferred embodiment isolated from said host organism. For example the cells can be isolated from spleen cells, lymph node cells or blood. T cell clones are selected for example via the surface expression of CD4 or CD8, depending on whether the TSA epitope is MHC class I or II. Methods for the isolation of single T cell clones form host or ganisms are well known for the person of skill in the art. The present invention is not restrict ed to a specific methodology for isolating T cells. However, in one preferred embodiment of the invention, said T cells or said T cell clone is after isolation further tested for the expres sion of a TCR binding to the TSA used in the method of the invention. This is preferably done WO 2014/083173 PCT/EP2013/075141 by tetramer binding (staining) using TSA specific HLA tetramers. Optionally, the isolated T cell or T cell clone is also tested for its specificity to the TSA compared with the un-mutated version of the cellular protein. To this end, T cell reactivity against peptides comprising the mutation and against peptides comprising the wild-type version is compared. In a preferred embodiment such T cells or T cell clones are isolated in accordance with the method of the invention, which are highly selective for the TSA and not the un-mutated version of the cellu lar protein. Another embodiment of the invention relates to a method as described herein, where after isolation of the T cell or T cell clone, the TCR sequence is cloned. In this embodiment the method in step d. as described above, comprises the further method steps of (i) preparing cDNA from said T-cell clone, and (ii) amplifying said cDNA, and (iii) cloning the respective TCR a and 0 genes into a vector. Preferably a retroviral vector for the transduction of human peripheral blood lymphocytes is used as a vehicle for the TCR of the invention. Means and methods for such a cloning procedure are well known to the skilled person. In another preferred embodiment of the invention the TSA used is expressed in a tumor cell or tumor disease. As used herein, the term "tumor " or "tumor disease" means both benign and malignant tu mors or neoplasms and includes melanomas, lymphomas, leukemias, carcinomas and sarco mas. Illustrative examples of tumor tissues are cutaneous such as malignant melanomas and mycosis fungoides; hematologic tumors such as leukemias, for example, acute lymphoblastic, acute myelocytic, or chronic myelocytic leukemia; lymphomas such as Hodgkin's disease or malignant lymphoma; gynecologic tumors such as ovarian and uterine tumors; urologic tu mors such as those of the prostate, bladder, or testis; soft tissue sarcomas, osseus, or non osseous sarcomas, breast tumors; tumors of the pituitary, thyroid, and adrenal cortex; gastro intestinal tumors such as those of the esophagus, stomach, intestine, and colon; pancreatic and hepatic tumors; laryngeae papillomestasas and lung tumors. Preferred tumors in the context of the present invention are selected from melanoma, lung tumor, endometrial tumors, glioma, lymphoma, leukemia or prostate tumor. Exemplary TSAs which can be subject to the inventive method described herein - without being limiting for the invention -are described in Krauthammer et al. 2012 (Nature Genetics).
WO 2014/083173 PCT/EP2013/075141 A preferred selection of TSAs which are presented by HLA type A2 are RAC1, RAC2, RHOTI, MAP2K1, MAP2K2, Nos1, EGFR, SMCA4, STKI1, ARID1A, RBM1O, U2AF1, EP300, CHD4, FBXW7, H3F3A, KLHL6, SPOP, or MED12. Their respective mutated epitope sequences are provided in the examples section herein below. The object of the present invention is furthermore solved by a nucleic acid molecule encoding for a TCR obtained or obtainable by the method in accordance with the present invention. Furthermore provided in the present invention are nucleic acid molecules which encode for the respective a a or 0 chains of an TCR of the invention, or for a variable or constant domain of a TCR of the invention, or for a fragment of a TCR of the invention, preferably wherein such a fragment of the TCR still has the activity/ability for binding its TSA. In addition to that, the nucleic acid molecule optionally has further sequences which are necessary for pro tein expression of the nucleic acid sequence, specifically for an expression in a mammali an/human, most preferably an immune cell. The nucleic acid used can be contained in a vector suitable for allowing expression of the nucleic acid sequence corresponding to the TCR in a cell. Also provided is a vector or a cell comprising a nucleic acid molecule described herein above, specifically wherein the vector is for use in medicine. Also a cell comprising a vector accord ing to the invention is provided. In another aspect the invention provides the T-cell receptor (TCR), or a fragment thereof, as obtained or obtainable by the method of the present invention. In this context it is specifically preferred that the TCR of the invention is a TCR which shows reduced adverse effects in im mune therapy. The TCR of the invention preferably does not target healthy cells or tissue, which express the un-mutated (wild-type) version of the TSA used for the generation of the TCR. The TCR of the invention in preferred embodiments does not induce necrosis events, and does not mount when given to subject an immune response against healthy cells or tissue. preferred TCR of the invention is a TCR specific for the epitope shown in SEQ ID No. 1. Preferably a TCR in accordance to the invention may be a TCR as described herein below. Yet another embodiment of the invention pertains to a single chain TCR (scTCR, preferably an a -scTCR, which are derived from a sequence of a TCR of the present invention. Single- WO 2014/083173 - 10 - PCT/EP2013/075141 chain TCRs (scTCRs) are artificial constructs consisting of a single amino acid strand. An scTCR can comprise a polypeptide of a variable region of a first TCR chain (e.g., an [alpha] chain) and a polypeptide of an entire (full-length) second TCR chain (e.g., a [beta] chain), or vice versa. Furthermore, the scTCR can optionally comprise one or more linkers which join the two or more polypeptides together. The linker can be, for instance, a peptide which joins together two single chains, as described herein. Also provided is such a scTCR of the invention or other TCR derived molecule of the inven tion, which is fused to a human cytokine, such as IL-2, IL-7 or IL-15. TCRs of the present invention can also be provided as a multimeric complex, comprising at least two scTCR or TCR molecules, wherein said scTCR or TCR molecules are interconnected for example by an introduced biotin-streptavidin functionality. In another aspect of the present invention a host cell is provided, comprising a vector a nucle ic acid or a TCR molecule as described herein above. In preferred embodiments of the inven tion the host cell is a human cell, preferably a human T-lymphocyte, which is positive for the expression of CD4 or CD8. Such a host cell of the invention is preferably obtained by trans duction of a nucleic acid or vector in accordance with the present invention. Transduction methods for introducing nucleic acid molecules into T cells are well known in the art and in clude without being limiting thereto viral transduction vehicles. In an alternative aspect of the invention a T-cell is provided obtained or obtainable by a meth od for the production of a human T cell receptor (TCR), which is specific for tumorous cells and has reduced adverse effects in adoptive T-cell therapy as described herein above. Such a T cell is depending on the host organism used in the method of the invention for example a human or non-human T-cell, preferably a non-human T-cell expressing a human TCR. The provided compounds of the invention are in a further aspect for use in medicine, for ex ample for use in the treatment of a cancerous disease, specifically wherein the cancerous dis ease is characterized by the specific expression of said mutated TSA. Most preferably the compounds of the invention are used in a cancer treatment that involves an adoptive T-cell transfer.
WO 2014/083173 11 PCT/EP2013/075141 Yet another aspect of the invention relates to a method of treating a human subject, specifical ly human subject suffering from a tumor disease. The method of treatment comprises the ad ministration of any of the aforementioned compounds into a patient in need of such a treat ment. The administration of the compounds of the invention can for example involve the infu sion of T cells of the invention into said patient. Preferably such T cells are autologous T cells of the patient which were in vitro transduced with a nucleic acid or TCR of the present inven tion. Thus also provided is a pharmaceutical composition, comprising a TCR or TCR fragment according to the invention, or a nucleic acid, a vector, a host cell, or an isolated T cell accord ing to the invention. In a preferred embodiment the pharmaceutical composition is for im mune therapy. Examples of pharmaceutically acceptable carriers or diluents useful in the present invention include stabilizers such as SPGA, carbohydrates (e.g. sorbitol, mannitol, starch, sucrose, glu cose, dextran), proteins such as albumin or casein, protein containing agents such as bovine serum or skimmed milk and buffers (e.g. phosphate buffer). Tumor antigens that are preferably used in the methods of the present invention to obtain a TCR of the invention are listed in tables 1 and 2 below (the mutation is indicated as amino acid exchange within the epitope in brackets): Table 1: Gene Protein Epitope Rac1 Ras-related C3 botulinum toxin substrate 1 27-35 (P29S) TRRAP transformation/transcription domain-associated protein 715-723 (S722F) Rac2 Ras-related C3 botulinum toxin substrate 2 28-36 (P29L) 28-36 (P29Q) Nos1 Nitric oxide synthase 770-779 (S771L) ARID1A AT-rich interactive domain-containing protein 1A 1999-2007 (E2000V) 1021-1031 (W1022L) H3F3A Histone H3.3 28-36 (G34V) KLHL6 Kelch-like protein 6 48-56 (F49L) ID3 Inhibitor of DNA binding 3 50-58 (L54V) FLT3 Fms-related tyrosine kinase 3 835-843 (D835Y) 835-843 (D835V) FBXW7 F-box/WD repeat-containing protein 7 456-464 (F462S) 456-464 (A463T) Med12 Mediator of RNA polymerase II transcription subunit 12 724-732 (D727E) CDK12 Cyclin-dependent kinase 12 898-906 (Y901C) CDC42 Cell division cycle 42 7-14 (G12V) SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator 1153-1161 WO 2014/083173 - 12 - PCT/EP2013/075141 of chromatin, subfamily a, member 4 (G1 159W) SMO Smoothened, frizzled family receptor 412-420 (L412F) SF3B1 Splicing factor 3b, subunit 1 693-701 (K700E) CHD4 Chromodomain-helicase-DNA-binding protein 4 907-916 (L912V) SPOP Speckle-type POZ protein 83-91 (Y87N) 83-91 (Y87C) MAP2K2 Dual specificity mitogen-activated protein kinase2 154-162 (S154F) Notch1 Notch1 1568-1576 (L1 574P) 1592-1600 (R1598P) FOXA1 Forkhead Box Al 221-229 (D226N) 2nd NT5C2 5'-Nucleotidase, Cytosolic II a) 233-241 b) 236-244 (R238L) 2"d Bcr-Abl Bcr-Abl 247-255 (E255K) RHOT1 Mitochondrial Rho GTPase 1 29-37 (P30L) MAP2K1 Dual specificity mitogen-activated protein kinasel 20-28 (E20K) EGFR Epidermal growth factor receptor 717-725 (G719A) 1125-1133 (H1129Y) STK1 1 Serine/threonine-protein kinas 219-228 (P221L) RBM10 RNA-binding protein 10 316-324 (1316F) U2AF1 Splicing factor U2AF 26 kDa subunit 28-36 (S34F) EP300 Histone acetyltransferase p300 1623-1631 (R1627W) CDK4 Cyclin-dependent kinase 4 23-32 (R24C) 23-32 (R24L) PPP6C Protein phosphatase 6, catalytic subunit 269-277 (S270L) TACC1 Transforming, acidic coiled-coil containing protein 1 792-801 (C794F) KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 5-14 (G12V) TRAF7 TNF receptor-associated factor 7, E3 ubiquitin protein ligase 518-527 (N520S) 531-541 (G536S) HIST1H3B Histone cluster 1, H3b 26-35 (K27M) ALK Anaplastic lymphoma receptor tyrosine kinase 1272-1280 (R1275Q) ABL1 C-abl oncogene 1, non-receptor tyrosine kinase 251-260 (E255K) 247-255 (E255V) CBL CbI proto-oncogene, E3 ubiquitin protein ligase 398-406 (H398Y) NPM1 Nucleophosmin (nucleolar phosphoprotein B23, numatrin) 283-291 (c.863_864insTCTG Insertion) 283-291 (c.863_864insCATG Insertion) 283-291 (c.863_864insCATG Insertion) EZH2 Enhancer of zeste homolog 2 637-645 (Y641 F) GNAS GNAS complex locus 201-210 (R201C) PDGFRA Platelet-derived growth factor receptor, alpha polypeptide 841-849 (D842V) TSHR Thyroid stimulating hormone receptor 451-459 (M453T) KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homo- 636-644 (K642E) log STAT3 Signal transducer and activator of transcription 3 a) 654-662 b) 659-667 (D661Y) CTNNB1 Catenin (cadherin-associated protein), beta 1 30-39 (S33C) 30-39 (S33F) 30-39 (S33Y) STK 1 Serine/threonine kinase 11 219-228 (P221L) ERBB2 V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 773-782 (G776V) SLIT2 Slit homolog 2 8-16 (M81) CDKN2A Cyclin-dependent kinase inhibitor 2A 113-121 (P114L) XPO1 Exportin 1 568-576 (E571K) WO 2014/083173 - 13 - PCT/EP2013/075141 The above described TCR of the invention pertain in preferred embodiments to the following TCR molecules: The present invention pertains to a TCR alpha chain, comprising a CDR3 region with the se quence shown in any one of SEQ ID NO: 28, 30, 32, 33, 36, 38 or 40. Preferred are TCR al pha chains comprising a variable domain having the sequence shown in any one of SEQ ID NO 42, 44, 46, 47, 50, 52, or 54. The present invention pertains to a TCR beta chain, comprising a CDR3 region with the se quence shown in any one of SEQ ID NO: 29, 31, 34, 35, 37, 39 or 41. Preferred are TCR beta chains comprising a variable domain having the sequence shown in any one of SEQ ID NO 43, 45, 48, 49, 51, 53, or 55. Preferred embodiments of the invention pertain to specific TCR isolated, or produced (ob tained) according to any one of the methods as described herein. Such TCRs of the invention are preferably TCRs specific for targeting a mutated antigen selected from table 1 or 2. The Rac-1 or TRRAP mutated antigen are preferred. More specifically such TCRs are preferred which have the capacity to specifically bind to the mutated Rac-1 epitope FSGEYIPTV, or the mutated TRAPP epitope KLVFGSVFL. Preferred TCR of the present invention are furthermore characterized by the presence of a CDR3 region comprising any one of the amino acid sequences shown in SEQ ID NO. 28 to 41. A Rac-1 TCR in accordance with the invention, with an alpha or beta chain, preferably comprises a CDR3 having a sequence shown in any one of SEQ ID NO: 28 to 39. A pre ferred TRRAP TCR in accordance with the present invention is characterized by the presence of a CDR3 amino acid sequence selected from the sequence shown in SEQ ID NO: 40 or 41. More preferred is an alpha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 28, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 29; an alpha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 30, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 31; an alpha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID WO 2014/083173 -14- PCT/EP2013/075141 NO: 32, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 34; an al pha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 32, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 35; an alpha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 33, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 34; an alpha/beta TCR hav ing an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 33, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 35; an alpha/beta TCR having an al pha chain comprising the CDR3 sequence shown in SEQ ID NO: 36, and a beta chain com prising the CDR3 sequence shown in SEQ ID NO: 37; an alpha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 38, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 39; an alpha/beta TCR having an alpha chain comprising the CDR3 sequence shown in SEQ ID NO: 40, and a beta chain comprising the CDR3 sequence shown in SEQ ID NO: 41. The TCR chains comprised in a TCR of the invention may furthermore comprise at least one, preferably two, most preferably all three CDR regions as present in one of the variable re gions of any one of TCR 1 to 7. The sequences of said variable regions which contain all three CDR regions are shown in SEQ ID NO 42 to 55. In another preferred embodiment the TCR of the invention comprises at least one variable region of an alpha and/or beta chain selected from a variable region of an alpha or beta chain of any one of the TCR TI to T7 of the invention as depicted herein below in table 3. The TCR as isolated in context of the present invention comprise the following variable re gions (CDR3 regions are underlined): Rac-1 TCR: TRAV20*02-CAVQTSQGGSEKLVF-TRAJ57*01 MEKMLECAFIV LWLQLGWLSG EDQVTQSPEA LRLQEGESSS LNCSYTVSGL RGLFWYRQDP GKGPEFLFTL YSAGEEKEKE RLKATLTKKE SFLHITAPKP EDSATYLCAV QTSQGGSEKL VFGKGTKLTV NPYIQNPEPA (SEQ ID NO:42) TRBV4-1*01-CASSQDASGIYYEQYF-TRBD2*02-TRBJ2-7*01 WO 2014/083173 - 15- PCT/EP2013/075141 MGCRLLCCAV LCLLGAVPID TEVTQTPKHL VMGMTNKKSL KCEQHMGHRA MYWYKQKAKK PPELMFVYSY EKLSINESVP SRFSPECPNS SLLNLHLHAL QPEDSALYLC ASSQDASGIY YEQYFGPGTR LTVT (SEQ ID NO:43) TRAV13-1*01-CAASRGGAQKLVF-TRAJ54*01 MTSIRAVFIF LWLQLDLVNG ENVEQHPSTL SVQEGDSAVI KCTYSDSASN YFPWYKQELG KGPQLIIDIR SNVGEKKDQR IAVTLNKTAK HFSLHITETQ PEDSAVYFCA ASRGGAQKLV FGQGTRLTIN PN (SEQ ID NO:44) TRBV3-1*01-CASSQLAGGPLYNEQFF-TRBD2*02-TRBJ2-1*01 MGCRLLCCVV FCLLQAGPLD TAVSQTPKYL VTQMGNDKSI KCEQNLGHDT MYWYKQDSKK FLKIMFSYNN KELIINETVP NRFSPKSPDK AHLNLHINSL ELGDSAVYFC ASSQLAGGPL YNEQFFGPGTRLTVL (SEQ ID NO:45) TRAV5*01-CAESKRFSDGQKLLF-TRAJ16*01 MR QVARVIVFLT LSMSRGEDVE QSLFLSVREG DSSVINCTYT DSSSTYLYWY KQEPGAGLQL LTYIFSNMDM KQDQRLTVLL NKKDKHLSLR IADTQTGDSA IYFCAESKRF SDGQKLLFAR GTMLKVDLN (SEQ ID NO:46) TRAV12-2*02-CAAQSARQLTF-TRAJ22*01 M MKSLRVLLVI LWLQLSWVWS QQKEVEQNSG PLSVPEGAIA SLNCTYSDRG SQSFFWYRQY SGKSPELIM SIYSNGDKED GRFTAQLNKA SQYVSLLIRD SQPSDSATYL CAAQSARQLT FGSGTQLTVL PD (SEQ ID NO:47) TRBV20-1*01(/02)-CSARDLITDTQYF-TRBJ2-3*01 MLLLLL LLGPGSGLGA VVSQHPSWVI CKSGTSVKIE CRSLDFQATT MFWYRQFPKQ SLMLMATSNE GSKATYEQGV EKDKFLINHA SLTLSTLTVT SAHPEDSSFY ICSARDLITD TQYFGPGTRL TVL (SEQ ID NO:48) TRBV3-1*01-CASSPWQETQYF-TRBJ2-5*01 MGCRLL CCVVFCLLQA GPLDTAVSQT PKYLVTQMGN DKSIKCEQNL GHDTMYWYKQ DSKKFLKIMF SYNNKELIIN ETVPNRFSPK SPDKAHLNLH INSLELGDSA VYFCASSPWQ ETQYFGPGTR LLVL (SEQ ID NO:49) WO 2014/083173 - 16- PCT/EP2013/075141 TRAV13-1*01 CAASLGSGNTPLVF TRAJ29*01 M TSIRAVFIFL WLQLDLVNGE NVEQHPSTLS VQEGDSAVIK CTYSDSASNY FPWYKQELGK GPQLIIDIRS NVGEKKDQRI AVTLNKTAKH FSLHITETQP EDSAVYFCAA SLGSGNTPLV FGKGTRLSVI AN (SEQ ID NO:50) TRBV28*01 CASSLHSGRDTQYF TRBJ2-3*01 TRBD2*02 MGIRLLCR VAFCFLAVGL VDVKVTQSSR YLVKRTGEKV FLECVQDMDH ENMFWYRQDP GLGLRLIYFS YDVKMKEKGD IPEGYSVSRE KKERFSLILE SASTNQTSMY LCASSLHSGR DTQYFGPGTR LTVL (SEQ ID NO:51) TRAV13-2*01 CAENRGANSKLTF TRAJ56*01 F MMAGIRALF MYLWLQLDWV SRGESVGLHL PTLSVQEGDN SIINCAYSNS ASDYFIWYKQ ESGKGPQFII DIRSNMDKRQ GQRVTVLLNK TVKHLSLQIA ATQPGDSAVY FCAENRGANS KLTFGKGITL SVRPD (SEQ ID NO:52) TRBV12-3*01 CASSFTGGFYGYTF TRBJ1-2*01 TRBD1*01 MDSWTFCCVS LCILVAKHTD AGVIQSPRHE VTEMGQEVTL RCKPISGHNS LFWYRQTMMR GLELLIYFNN NVPIDDSGMP EDRFSAKMPN ASFSTLKIQP SEPRDSAVYF CASSFTGGFY GYTFGSGTRL TVV (SEQ ID NO:53) TRRAP TCR: TRAV17*01-CATDWYTGANSKLTF-TRAJ56*01 METLLGVSLV ILWLQLARVN SQQGEEDPQA LSIQEGENAT MNCSYKTSIN NLQWYRQNSG RGLVHLILIR SNEREKHSGR LRVTLDTSKK SSSLLITASR AADTASYFCA TDWYTGANSK LTFGKGITLS VRPD (SEQ ID NO:54) TRBV6-2*01-CASSYSGYEQYF-TRBD1*01-TRBJ2-7*01 MSLGLLCCAA FSLLWAGPVN AGVTQTPKFR VLKTGQSMTL LCAQDMNHEY MYWYRQDPGM GLRLIHYSVG EGTTAKGEVP WO 2014/083173 - 17- PCT/EP2013/075141 DGYNVSRLKK QNFLLGLESA APSQTSVYFC ASSYSGYEQY FGPGTRLTVT (SEQ ID NO:55) One further preferred embodiment of the invention provides a TCR alpha and/or beta chain, or a fragment thereof, comprising a sequence selected from the group of SEQ ID NO 42 to 55. Preferably the TCR of the invention is heterodimeric TCR comprising an alpha chain comprising a sequence according to SEQ ID NO 42, and a beta chain comprising a sequence according to SEQ ID NO 43, or comprising an alpha chain comprising a sequence according to SEQ ID NO 44, and a beta chain comprising a sequence according to SEQ ID NO 45, or comprising an alpha chain comprising a sequence according to SEQ ID NO 46, and a beta chain comprising a sequence according to SEQ ID NO 48, or comprising an alpha chain com prising a sequence according to SEQ ID NO 46, and a beta chain comprising a sequence ac cording to SEQ ID NO 49, or comprising an alpha chain comprising a sequence according to SEQ ID NO 47, and a beta chain comprising a sequence according to SEQ ID NO 48, or comprising an alpha chain comprising a sequence according to SEQ ID NO 47, and a beta chain comprising a sequence according to SEQ ID NO 49, or comprising an alpha chain com prising a sequence according to SEQ ID NO 50, and a beta chain comprising a sequence ac cording to SEQ ID NO 51, or comprising an alpha chain comprising a sequence according to SEQ ID NO 52, and a beta chain comprising a sequence according to SEQ ID NO 53, or comprising an alpha chain comprising a sequence according to SEQ ID NO 54, and a beta chain comprising a sequence according to SEQ ID NO 55. In even more preferred aspects of the invention the TCR of the invention is a TCR comprising at least one TCR alpha or beta chain selected from the TCR chains of any one of TCRs TI to T7 in table 3 below. Most preferred is that the TCR of the invention is an alpha/beta TCR selected from any one of TI to T7 as depicted in table 3 herein below. The aforementioned TCRs of the invention may in some embodiments contain altered amino acid sequences. Preferred is that TCR chains are encompassed by the present invention which are at least 70, 80, 90, 95, 96, 97, 98, or 99 % identical to a TCR sequence, or TCR alpha or beta chain sequence, a TCR variable region according to any one of SEQ ID NO: 42 to 55, or a CDR3 sequence as disclosed herein. Most preferably a TCR of the invention comprises an WO 2014/083173 -18- PCT/EP2013/075141 alpha and/or beta chain which is at least 90%, or 95%, or 99% identical to an alpha/beta chain of any one of TCRs TI to T7 as depicted in table 3. The above described TCR are preferably specific for the mutated antigens of Rac-1 or TRRAP as disclosed in table 1 or 2, in particular when presented on a cell, such as a tumor cell or antigen presenting cell. Furthermore comprised by the present invention are functional fragments of the TCR or TCR chains of the invention. The term "functional fragment of the TCR or TCR chain" shall refer to a fragment of the full length receptor molecule, character ized in that the fragment is derived from that molecule and has maintained the same capability to bind the mutated TAA. In a further aspect, as already disclosed above, the invention also pertains to the nucleic acids encoding for the TCR molecules of the invention as well as cells comprising these nucleic acids, or cells expressing said TCRs of the invention. The invention furthermore pertains to the use of the TCR proteins or nucleic acids, or cells, in the various methods or uses described herein before. Preferably aspects of the invention relate to the treatment of tumorous diseases with the meth ods and various materials of the invention. Preferred diseases are cancers which are character ized by the expression of any one of the mutated TAA as disclosed herein. Preferred is a dis ease that is characterized by the expression of the mutated epitope of Rac- 1 or TRRAP. Pre ferred diseases treated with a TCR of the invention that is specific for the Rac-1 mutated anti gen or the TRRAP mutated antigen are selected from cancerous proliferative diseases, e.g. lung cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, leu kemia, liver cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal can cer, sarcoma, skin cancer, testicular cancer, and uterine cancer. Particular preferred diseases for RacI specific TCRs are melanoma and non-small cell lung cancer. The present invention will now be further described in the following examples with reference to the accompanying figures and sequences, nevertheless, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by refer ence in their entireties. In the Figures and Sequences: WO 2014/083173 - 19- PCT/EP2013/075141 Figure 1: shows the specific CD8+ T cell response against HLA-A201 restricted mutated RAC1P29S epitope in ABabDII mice. SEQ ID No 1 to 27: show mutated epitope sequences of HLA type A2 restricted TSAs as depicted in Table 1. SEQ ID No 28 to 41: show the CDR3 domain sequences of the TCR of the invention. SEQ ID No 42 to 55: show the variable regions of the TCR 1 to 7 of the invention.
WO 2014/083173 - 20 - PCT/EP2013/075141 EXAMPLES Exemplary tumor specific antigen epitopes which are usable and preferred in the context of the present invention are provided in table 2. Gene Protein H LAA2.LEpitope MELANOMA RAC1: Ras-related C3 botulinum toxin substrate 1 FP/SGEYIPTV RAC2: Ras-related C3 botulinum toxin substrate 1 FP/LGEYIPTV RHOT1: Mitochondrial Rho GTPase 1 FP/LEEVPPRA MAP2K1: Dual specificity mitogen-activated protein kinasel E/KIKLCDFGV MAP2K2: Dual specificity mitogen-activated protein kinase2 E/KIKLCDFGV S/FLDQVLKEA Nos1: Nitric oxide synthase KS/LQAYAKTL LUNG TUMOR EGFR: Epidermal growth factor receptor VLG/ASGAFGT SMCA4: Transcription activator BRG1 LLSTRAG/WGL STK1 1: Serine/threonine-protein kinas FQP/LPEIANGL ARID1A: AT-rich interactive domain-containing protein 1A MW/LVDRYLAFT FENMSKHPGL RBM10: RNA-binding protein 10 I/FLGALAPYA U2AF1: Splicing factor U2AF 26 kDa subunit RHGDRCS/FRL ENDOMETRIAL TUMORS EP300: Histone acetyltransferase p300 LMDGR/WDAFL LMDGR/QDAFL CHD4 Chromodomain-helicase-DNA-binding protein 4 NLEEL/VFHLL FBXW7: F-box/WD repeat-containing protein 7 TLYGHTF/SAV TLYGHTFA/TV GLIOMA H3F3A: Histone H3.3 QLATKAARK/M KSAPSTGNGV CLL KLHL6: Kelch-like protein 6 KF/LDDAGLSL PROSTATE TUMOR SPOP: Speckle-type POZ protein YLSLY/NLLLV YLSLY/CLLLV FVQGKDWGFN FVQGKDWGF/L MED12: Mediator of RNA polymerase II transcription subunit VLYD/EQPRHV 12 *wildtype/mutated amino acid WO 2014/083173 - 21 - PCT/EP2013/075141 Example 1: RAC1 specific TCR against the FSGEYIPTV Epitope For the generation of T-cells bearing a RAC 1 TSA specific TCR, mice deficient in their en dogenous TCR loci and expressing the human TCR repertoire were used. The production and setup of the transgenic mice (ABabDII mice) are in detail described elsewhere (Li LP, Lam pert JC, Chen X, Leitao C, Popovic J, Muller W, et al. Transgenic mice with a diverse human T cell antigen receptor repertoire. Nat Med. 2010;16:1029-34.). ABabDII mice were immunized twice with mutated RAC1P29S epitope (see above). Seven days after the last immunization, pooled spleen and lymph node cells were stimulated in vitro with RACI mutant or wildtype peptides and analyzed for expression of CD3, CD8 and intra cellular IFN-y. Figure 1 shows CD8+ and IFN-y+ cells within the CD3+ cell population (per centages indicated by numbers). In parentheses, the percentage of CD8+ and IFN-y+ T cells within the CD8+ T cell population is given. Example 2: RAC 1 and TRRAP specific TCR of the Invention Table 3: The following TCR could be isolated: peptide/purifi TCR Antigen cation TCR sequence CDR3* TRAV20*02-CAVQTSQGGSEKLVF Ti Rac-1 FSGEYIPTV TRAJ57*01 28 TRBV4-1*01-CASSQDASGIYYEQYF IFNg-CAPTURE TRBD2*02-TRBJ2-7*01 29 TRAV13-1*01-CAASRGGAQKLVF T2 Rac-1 FSGEYIPTV TRAJ54*01 30 TRBV3-1*01-CASSQLAGGPLYNEQFF IFNg-CAPTURE TRBD2*02-TRBJ2-1*01 31 TRAV5*01-CAESKRFSDGQKLLF T3/T4 Rac-1 FSGEYIPTV TRAJ16*01 32 TRAV12-2*02-CAAQSARQLTF A2-TETRAMER TRAJ22*01 33 TRBV20-1*01 (/02)-CSARDLITDTQYF TRBJ2-3*01 34 TRBV3-1*01-CASSPWQETQYF-TRBJ2 5*01 35 TRAV13-1*01 CAASLGSGNTPLVF T5 Rac-1 FSGEYIPTV TRAJ29*01 36 TRBV28*01 CASSLHSGRDTQYF A2-TETRAMER TRBJ2-3*01 TRBD2*02 37 TRAV13-2*01 CAENRGANSKLTF T6 Rac-1 FSGEYIPTV TRAJ56*01 F 38 A2-TETRAMER TRBV12-3*01 CASSFTGGFYGYTF 39 WO 2014/083173 - 22 - PCT/EP2013/075141 TRBJ1-2*01 TRBD1*01 TRAV17*01-CATDWYTGANSKLTF T7 TRRAP KLVFGSVFL TRAJ56*01 40 TRBV6-2*01-CASSYSGYEQYF IFNg-CAPTURE TRBD1*01-TRBJ2-7*01 41 *Sequence identifier Table 3 provides the sequences of the alpha and beta chains of the isolated TCR of the inven tion (TI to T7). The sequences are presented by the known TCR allele sequence and the spe cific CDR3 amino acid sequence of the TCR of the invention. TCR allele nomenclature is derived from the TCR allele Database IMGT (http://www.imgt.org/vquest/refseqh.html#VQUEST) Lefranc, M.-P. and Lefranc, G. The T cell receptor FactsBook Academic Press, London, UK (398 pages), (2001). The variable regions of the TCR chains of the TCR 1 to 7 are provided in SEQ ID No 42 to 55. For T3/T4, the inventors discovered that in particular the chain combination TRAV5/TRBV20-1 (SEQ ID NO: 32 and34) shows good binding to the RacI-tetramer.
Claims (30)
1. A method for the production of a human T cell receptor (TCR), which is specific for tumorous cells and has reduced adverse effects in adoptive T-cell therapy, comprising a. Providing a host organism expressing unrearranged human TCR loci, b. Immunizing said host organism with a peptide comprising an epitope specific for a tumor specific antigen (TSA), c. Isolating from said host organism a T cell clone having an activity against said human mutated TSA, d. Optionally, isolating from said T cell clone the TCR, wherein said TSA is selected out of the class of somatic mutated antigens.
2. The method according to claim 1, wherein said host organism further comprises a transgene for the expression of a human major histocompatibility complex (MHC) class I or II, preferably the human leucocyte antigen (HLA) type which is known to present said mutated TSA.
3. The method according to claim 1 or 2, wherein said unrearranged human TCR loci are present as one or more transgenes in the genome of said host organism.
4. The method according to any one of claims 1 to 3, wherein said human TCR loci en code TCR a and 0 chains, and preferably comprise a plurality of TCR V, D, J, and/or C genes.
5. The method according to any one of claims 1 to 4, wherein said host organism has an adaptive immune system and/or is able to mount a VDJC rearrangement and expres sion of heterologous TCRs; preferably said host organism is a transgenic animal, pref erably a mammal, more preferably a non-human mammal, most preferably a mouse, a rat, a donkey, a rabbit, a hare or a monkey. WO 2014/083173 PCT/EP2013/075141 - 24
6. The method according to any one of claims 1 to 3, wherein said host organism further comprises inactivated endogenous TCR loci, preferably wherein said endogenous TCR loci encode for TCR a and 0 chains.
7. The method according to any one of claims 1 to 4, wherein said host organism is an ABabDII mouse.
8. The method according to any one of claims 1 to 7, wherein said peptide comprises an amino acid sequence which is in at least one amino acid residue mutated compared to the amino acid sequence of the corresponding wild-type cellular protein.
9. The method according to claim 8, wherein a mutation is selected from a substitution, deletion, addition, insertion, chromosomal translocation or chemical or post translational modification of said at least one amino acid residue.
10. The method according to any one of claims I to 9, wherein said peptide has a length of 100 amino acids, preferably of 50 amino acids, more preferably of 30 amino acids, even more preferably 8 to 16 amino acids.
11. The method according to any one of claims I to 10, wherein in step b. CpG and in complete Freunds adjuvant is additionally administered to said host-organism to en hance immunization efficiency.
12. The method according to any one of claims I to 11, wherein after initial immunization, said host organisms is treated at least one or more times with said peptide plus CpG and incomplete Freunds adjuvant.
13. The method according to any one of claims 1 to 12, wherein said T-cell clone is isolat ed from spleen cells, lymph node cells or blood of said host organism.
14. The method according to any one of claims I to 13, wherein step d., comprises the fur ther method steps of (i) preparing cDNA from said T-cell clone, and (ii) amplifying said cDNA, and (iii) cloning the respective TCR a and 0 genes into a vector.
15. The method according to claim 14, wherein said vector is a retroviral vector for the transduction of human peripheral blood lymphocytes. WO 2014/083173 - 25 - PCT/EP2013/075141
16. The method according to any one of claims 1 to 15, wherein said mutated TSA is ex pressed in a tumor selected from melanoma, lung tumor, endometrial tumors, glioma, lymphoma, leukemia or prostate tumor.
17. The method according to any one of claims 1 to 15, wherein said mutated TAA is se lected from RACI, RAC2, RHOTI, MAP2K1, MAP2K2, Nos1, EGFR, SMCA4, STKI, ARID1A, RBM1O, U2AF1, EP300, CHD4, FBXW7, H3F3A, KLHL6, SPOP, or MED12.
18. A nucleic acid molecule encoding for a TCR obtained by the method according to any one of claims 1 to 17, or for an a or 0 chain thereof, or for a variable or constant do main thereof, or for a fragment thereof having the ability to bind to said mutated TSA.
19. A vector comprising a nucleic acid according to claims 18.
20. A TCR obtainable by a method according to any one of claims 1 to 17, or a a or chain thereof, or a variable or constant domain thereof, or a fragment thereof having the ability to bind to said mutated TAA antigenic fragments thereof.
21. A TCR comprising an alpha and/or beta chain, wherein said alpha and/or beta chain comprises at least one CDR3 domain according to any one of SEQ ID NO: 28 to 41.
22. The TCR according to claim 21, wherein said TCR comprises at least one variable re gion selected from a variable region of a TCR single chain of any one of TCR TI to T7 in table 3, preferably wherein said variable region comprises a sequence according to any one of SEQ ID NO 42 to 55.
23. A host cell, comprising a vector according to claim 19, a nucleic acid according to claim 18 or a TCR according to any one of claims 20 to 22.
24. The host cell according to claim 23, which is a human cell, preferably a T-cell.
25. The host cell according to claim 23, which is a CD4 or CD8 positive T-cell.
26. A non-human T-cell, obtainable by a method according to any one of claims I to 17.
27. The non-human T-cell according to claim 26, wherein the T-cell is a non-human T-cell expressing a human TCR. WO 2014/083173 PCT/EP2013/075141 - 26
28. A nucleic acid molecule according to claim 18, a vector according to claim 19, a TCR according to any one of claims 20 to 22 or a host cell according to any one of claims 23 to 25, for use in medicine.
29. The nucleic acid molecule, a vector, a TCR or a host cell according to claim 28, for use in the treatment of a cancerous disease, specifically wherein the cancerous disease is characterized by the specific expression of said mutated TSA.
30. The nucleic acid molecule, a vector, a TCR or a host cell according to claim 29, wherein said treatment involves adoptive T-cell therapy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2018203663A AU2018203663A1 (en) | 2012-11-30 | 2018-05-24 | Tumor specific t-cell receptors |
AU2020200092A AU2020200092A1 (en) | 2012-11-30 | 2020-01-07 | Tumor specific t-cell receptors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261731666P | 2012-11-30 | 2012-11-30 | |
GB1221628.9 | 2012-11-30 | ||
GB1221628.9A GB2508414A (en) | 2012-11-30 | 2012-11-30 | Tumour specific T cell receptors (TCRs) |
US61/731,666 | 2012-11-30 | ||
PCT/EP2013/075141 WO2014083173A1 (en) | 2012-11-30 | 2013-11-29 | Tumor specific t-cell receptors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018203663A Division AU2018203663A1 (en) | 2012-11-30 | 2018-05-24 | Tumor specific t-cell receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013351062A1 true AU2013351062A1 (en) | 2015-06-04 |
AU2013351062B2 AU2013351062B2 (en) | 2018-03-22 |
Family
ID=50683754
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013351062A Active AU2013351062B2 (en) | 2012-11-30 | 2013-11-29 | Tumor specific T-cell receptors |
AU2018203663A Abandoned AU2018203663A1 (en) | 2012-11-30 | 2018-05-24 | Tumor specific t-cell receptors |
AU2020200092A Abandoned AU2020200092A1 (en) | 2012-11-30 | 2020-01-07 | Tumor specific t-cell receptors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018203663A Abandoned AU2018203663A1 (en) | 2012-11-30 | 2018-05-24 | Tumor specific t-cell receptors |
AU2020200092A Abandoned AU2020200092A1 (en) | 2012-11-30 | 2020-01-07 | Tumor specific t-cell receptors |
Country Status (9)
Country | Link |
---|---|
US (1) | US10683336B2 (en) |
EP (1) | EP2925349B1 (en) |
JP (1) | JP6615612B2 (en) |
CN (1) | CN104853765B (en) |
AU (3) | AU2013351062B2 (en) |
CA (1) | CA2891967A1 (en) |
GB (1) | GB2508414A (en) |
HK (1) | HK1214942A1 (en) |
WO (1) | WO2014083173A1 (en) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101441843B1 (en) | 2005-10-18 | 2014-09-17 | 내셔날 쥬이쉬 헬스 | Conditionally immortalized long-term stem cells and methods of making and using such cells |
EP2285832B1 (en) | 2008-05-16 | 2020-08-26 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
AU2009285547B2 (en) | 2008-08-28 | 2012-05-31 | Taiga Biotechnologies, Inc. | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
CA2879667C (en) | 2012-07-20 | 2021-11-16 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
US10801070B2 (en) | 2013-11-25 | 2020-10-13 | The Broad Institute, Inc. | Compositions and methods for diagnosing, evaluating and treating cancer |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
CN103865998B (en) * | 2013-12-16 | 2016-04-20 | 周菊华 | A kind of gene tester of immunotherapy of tumors effect |
CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
KR20170076775A (en) * | 2014-10-31 | 2017-07-04 | 베일러 칼리지 오브 메디신 | Survivin specific t-cell receptor targeting tumor but not t cells |
US20190030071A1 (en) | 2014-11-03 | 2019-01-31 | IMMURES S.r.I. | T cell receptors |
EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
US10441644B2 (en) | 2015-05-05 | 2019-10-15 | The Regents Of The University Of California | H3.3 CTL peptides and uses thereof |
CN116196401A (en) | 2015-05-20 | 2023-06-02 | 博德研究所 | Consensus neoantigens |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
EP3202784A1 (en) * | 2016-02-08 | 2017-08-09 | Polybiocept AB | T-cell receptor sequences for active immunotherapy |
GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
EP3443123B1 (en) | 2016-04-11 | 2021-08-11 | Board of Regents, The University of Texas System | Methods and compositions for detecting single t cell receptor affinity and sequence |
WO2017184590A1 (en) | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
WO2018035364A1 (en) | 2016-08-17 | 2018-02-22 | The Broad Institute Inc. | Product and methods useful for modulating and evaluating immune responses |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
CN106367518A (en) * | 2016-09-28 | 2017-02-01 | 湖北工业大学 | Reagent for detecting gene mutation of Ras related C3 butulinum toxins 1 and application |
WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
GB2605540B (en) | 2016-10-18 | 2022-12-21 | Univ Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
CN113786476A (en) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | Nanoparticle formulations |
DE102016123893A1 (en) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T cell receptors with improved binding |
EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
EP4287191A3 (en) | 2017-02-12 | 2024-03-06 | BioNTech US Inc. | Hla-based methods and compositions and uses thereof |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
WO2018191553A1 (en) | 2017-04-12 | 2018-10-18 | Massachusetts Eye And Ear Infirmary | Tumor signature for metastasis, compositions of matter methods of use thereof |
EP3612629A1 (en) | 2017-04-18 | 2020-02-26 | The Broad Institute, Inc. | Compositions for detecting secretion and methods of use |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
AU2017425657A1 (en) | 2017-08-03 | 2020-02-13 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
JP2020535802A (en) | 2017-09-21 | 2020-12-10 | ザ・ブロード・インスティテュート・インコーポレイテッド | Systems, methods, and compositions for targeting nucleic acid editing |
US11732257B2 (en) | 2017-10-23 | 2023-08-22 | Massachusetts Institute Of Technology | Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
CN110627895B (en) * | 2018-06-25 | 2021-03-23 | 北京大学 | Lung cancer specific TCR and analysis technology and application thereof |
US20210324357A1 (en) | 2018-08-20 | 2021-10-21 | The Brigham And Women's Hospital, Inc. | Degradation domain modifications for spatio-temporal control of rna-guided nucleases |
US20210177832A1 (en) | 2018-08-20 | 2021-06-17 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease target binding and uses thereof |
US20210355522A1 (en) | 2018-08-20 | 2021-11-18 | The Broad Institute, Inc. | Inhibitors of rna-guided nuclease activity and uses thereof |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
US20220170097A1 (en) | 2018-10-29 | 2022-06-02 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
BR112021012278A2 (en) | 2018-12-21 | 2021-12-14 | Biontech Us Inc | Method and system for the preparation of epitope-specific class II HLA cells and CD4+T synthesis |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
KR20210144679A (en) * | 2019-03-21 | 2021-11-30 | 알로젠 테라퓨틱스 인코포레이티드 | How to Improve TCRαβ+ Cell Depletion Efficiency |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
US20230031784A1 (en) * | 2019-11-26 | 2023-02-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | T cell receptors targeting mutations in rna splicing factors |
US11865168B2 (en) | 2019-12-30 | 2024-01-09 | Massachusetts Institute Of Technology | Compositions and methods for treating bacterial infections |
EP4110938A1 (en) * | 2020-02-27 | 2023-01-04 | Board of Regents, The University of Texas System | Engineered t cell receptors and methods of use |
US20240150711A1 (en) | 2021-03-01 | 2024-05-09 | Dana-Farber Cancer Institute, Inc. | Personalized redirection and reprogramming of t cells for precise targeting of tumors |
EP4323389A1 (en) * | 2021-04-15 | 2024-02-21 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
EP4079753A1 (en) * | 2021-04-20 | 2022-10-26 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | T-cell receptors specific for both rac1- and rac2-derived mutated epitopes |
EP4215042A1 (en) * | 2022-01-21 | 2023-07-26 | Max-Delbrück-Centrum für Molekulare Medizin | A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereof |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763164A (en) * | 1993-04-16 | 1998-06-09 | Northwestern University | Immunogenic cancer proteins and peptides and methods of use |
US5830755A (en) * | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
WO2002059263A2 (en) * | 2000-12-19 | 2002-08-01 | Sunol Molecular Corporation | Transgenic animals comprising a humanized immune system |
US8486694B2 (en) * | 2005-08-05 | 2013-07-16 | Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH | Generation of antigen specific T cells |
AU2006293420B2 (en) * | 2005-09-22 | 2011-06-30 | Irun R. Cohen | Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom |
CN103374576A (en) | 2007-03-05 | 2013-10-30 | 株式会社癌免疫研究所 | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
US8105831B2 (en) * | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
ES2788863T3 (en) * | 2010-05-14 | 2020-10-23 | Massachusetts Gen Hospital | Compositions of tumor-specific neoantigens for use in treating tumors |
EP3213765B1 (en) * | 2010-09-20 | 2019-08-28 | BioNTech Cell & Gene Therapies GmbH | Antigen-specific t cell receptors and t cell epitopes |
KR102321909B1 (en) * | 2011-10-28 | 2021-11-05 | 리제너론 파아마슈티컬스, 인크. | Genetically modified t cell receptor mice |
EP2883884A4 (en) * | 2012-08-10 | 2016-08-10 | Kanagawa Prefectural Hospital Organization | Antigen peptide originated from t790m point-mutated sequence of epidermal growth factor receptor |
-
2012
- 2012-11-30 GB GB1221628.9A patent/GB2508414A/en not_active Withdrawn
-
2013
- 2013-11-29 AU AU2013351062A patent/AU2013351062B2/en active Active
- 2013-11-29 CA CA2891967A patent/CA2891967A1/en active Pending
- 2013-11-29 EP EP13796113.2A patent/EP2925349B1/en active Active
- 2013-11-29 US US14/648,314 patent/US10683336B2/en active Active
- 2013-11-29 JP JP2015544487A patent/JP6615612B2/en active Active
- 2013-11-29 WO PCT/EP2013/075141 patent/WO2014083173A1/en active Application Filing
- 2013-11-29 CN CN201380062554.8A patent/CN104853765B/en active Active
-
2016
- 2016-03-11 HK HK16102860.5A patent/HK1214942A1/en unknown
-
2018
- 2018-05-24 AU AU2018203663A patent/AU2018203663A1/en not_active Abandoned
-
2020
- 2020-01-07 AU AU2020200092A patent/AU2020200092A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104853765B (en) | 2019-06-28 |
EP2925349A1 (en) | 2015-10-07 |
AU2018203663A1 (en) | 2018-06-07 |
AU2020200092A1 (en) | 2020-01-30 |
CA2891967A1 (en) | 2014-06-05 |
WO2014083173A1 (en) | 2014-06-05 |
HK1214942A1 (en) | 2016-08-12 |
EP2925349B1 (en) | 2019-05-08 |
GB2508414A (en) | 2014-06-04 |
AU2013351062B2 (en) | 2018-03-22 |
JP6615612B2 (en) | 2019-12-04 |
JP2015536665A (en) | 2015-12-24 |
CN104853765A (en) | 2015-08-19 |
US20150307585A1 (en) | 2015-10-29 |
US10683336B2 (en) | 2020-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10683336B2 (en) | Tumor specific T-cell receptors | |
AU2018204891B2 (en) | High avidity binding molecules recognizing mage-a1 | |
AU2022202307B2 (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
TWI730306B (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
AU2016239920B2 (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors | |
Baxevanis et al. | HER-2/neu as a target for cancer vaccines | |
ES2786049T3 (en) | Antibodies and fragments thereof generated against the ALPHA-3 domain of the HLA-G protein, methods and means for their preparation and uses thereof | |
Ferrone et al. | Tumor microenvironment and immune escape | |
CN109152813B (en) | Novel peptides, peptide compositions as targets for gallbladder and bile duct cancer and other cancer immunotherapy | |
JP5934897B2 (en) | T cell receptor β chain gene and α chain gene | |
AU2016259730A1 (en) | Claudin-18.2-specific immunoreceptors and T cell epitopes | |
JP7217981B2 (en) | Novel peptides and peptide combinations for use in immunotherapy against various tumors | |
Matsuzaki et al. | A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells | |
CN106279392B (en) | Tumor associated antigen XAGE-1b small peptides and its application | |
CN113795586A (en) | T cell receptors and methods of use thereof | |
Pupa et al. | HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine | |
JP2021502110A (en) | Screening of T lymphocytes for cancer-specific antigens | |
Labarriere et al. | Is antigen specificity the key to efficient adoptive T-cell therapy? | |
EP4091627A1 (en) | Tcr constructs specific for magea4-derived epitopes | |
TW202126676A (en) | Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers | |
TW202116792A (en) | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers | |
JPWO2005007694A1 (en) | HER2 / neu peptide and its therapeutic use | |
Çakmak-Görür | Targeting the hematopoietic stem cell antigen FLT3 by high-affinity T cell receptor for the treatment of high-risk acute myeloid leukemia | |
CN109265517B (en) | Peptides and peptide compositions for use in various tumor immunotherapy | |
Smith | Treating cancer with engineered T cell therapies: Murine and canine models of safety and efficacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |